Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects (Clinical Pharmacology and Therapeutics (2008) 83, (749-757) DOI: 10.1038/sj.clpt.6100336);Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 5, 2008, Pages 749-757

  Kuhne A ^a   Sezer, O ^b   Heider, U ^b   Meineke, I ^a   Muhlke, S ^a   Niere, W ^a   Overbeck, T ^a   Hohloch, K ^a   Trumper L ^a   Brockmoller J ^a   Kaiser, R ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MELPHALAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG MONITORING; FEMALE; GENE DELETION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 42349099009     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.85     Document Type: Erratum

References (36)

1. Alexanian, R. et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208, 1680-1685 (1969).
2. Alexanian, R. & Dimopoulos, M. The treatment of multiple myeloma. N. Engl. J. Med. 330, 484-489 (1994).
3. Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335, 91-97 (1996).
4. Child, J.A. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875-1883 (2003).
5. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 23, 1003-1006 (1999).
6. Moreau, P., Le Bonniec, M. & Harousseau, J.L. High-dose melphalan in patients with multiple myeloma. Bull. Cancer 86, 283-288 (1999).
7. Samuels, B.L. & Bitran, J.D. High-dose intravenous melphalan: a review. J. Clin. Oncol. 13, 1786-1799 (1995).
8. Kergueris, M.F., Milpied, N., Moreau, P., Harousseau, J.L. & Larousse, C. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res. 14, 2379-2382 (1994).
9. Bosanquet, A.G. & Gilby, E.D. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur. J. Cancer Clin. Oncol. 18, 355-362 (1982).
10. Pinguet, F. et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res. 17, 605-611 (1997).
11. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br. J. Haematol. 95, 527-530 (1996).
12. Reece, P.A. et al. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother. Pharmacol. 22, 348-352 (1988).
13. Mougenot, P. et al. Population pharmacokinetics of melphalan infused over a 24-h period, in patients with advanced malignancies. Cancer Chemother. Pharmacol. 53, 503-512 (2004).
14. Suzukake, K., Petro, B.J. & Vistica, D.T. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem. Pharmacol. 31, 121-124 (1982).
15. Suzukake, K., Vistica, B.P. & Vistica, D.T. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol. 32, 165-167 (1983).
16. Rothbarth, J., Vahrmeijer, A.L. & Mulder, G.J. Modulation of cytostatic efficacy of melphalan by glutathione: mechanisms and efficacy. Chem. Biol. Interact. 140, 93-107 (2002).
17. Mannervik, B. et al. Nomenclature for human glutathione transferases. Biochem. J. 282 (Part 1), 305-306 (1992).
18. Hall, A.G., Matheson, E., Hickson, I.D., Foster, S.A. & Hogarth, L. Purification of an alpha class glutathione S-transferase from melphalan-resistant Chinese hamster ovary cells and demonstration of its ability to catalyze melphalan-glutathione adduct formation. Cancer Res. 54, 3369-3372 (1994).
19. Bolton, M.G., Colvin, O.M. & Hilton, J. Specificity of isozymes of murine hepatic glutathione S-transferase for the conjugation of glutathione with L-phenylalanine mustard. Cancer Res. 51, 2410-2415 (1991).
20. Awasthi, S. et al. Interactions of melphalan with glutathione and the role of glutathione S-transferase. Drug Metab. Dispos. 24, 371-374 (1996).
21. Qian, Q., Yan, W. & Yang, C.Z. Mechanisms of resistance to melphalan in leukemia cell line and reversal by interferon alpha. Zhonghua Yi Xue Za Zhi 76, 485-489 (1996).
22. Bredschneider, M. et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin. Pharmacol. Ther. 71, 479-487 (2002).
23. Zimniak, P. et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem. 224, 893-899 (1994).
24. Watson, M.A., Stewart, R.K., Smith, G.B., Massey, T.E. & Bell, D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19, 275-280 (1998).
25. Seidegard, J., Vorachek, W.R., Pero, R.W. & Pearson, W.R. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. USA 85, 7293-7297 (1988).
26. Brockmoller, J., Kerb, R., Drakoulis, N., Staffeldt, B. & Roots, I. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res. 54, 4103-4111 (1994).
27. Pemble, S. et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. 300 (Part 1), 271-276 (1994).
28. Brockmoller, J., Cascorbi, I., Kerb, R. & Roots, I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56, 3915-3925 (1996).
29. Pinguet, F. et al. A phase I and pharmacokinetic study of melphalan using a 24-h continuous infusion in patients with advanced malignancies. Clin. Cancer Res. 6, 57-63 (2000).
30. Cockcroft, D.W. & Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
31. Osterheld, H.K., Musch, E., von Unruh, G.E., Loos, U., Rauschecker, H. & Muhlenbruch, B.J. A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma. Cancer Chemother. Pharmacol. 21, 156-162 (1988).
32. Aarskog, N.K. & Vedeler, C.A. Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum. Genet. 107, 494-498 (2000).
33. Wang, Y., Spitz, M.R., Schabath, M.B., Ali-Osman, F., Mata, H. & Wu, X. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. Lung Cancer 40, 25-32 (2003).
34. NONMEM-Project-Group. NONMEM Users Guides (NONMEM-Project-Group, San Francisco, CA, 1992).
35. Mandema, J.W. et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 7, E513-E522 (2005).
36. Jonsson, E.N. & Karlsson, M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).